BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...By BioCentury Staff Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its...
...immediately but remains subject to comment. TARGETSSGLT1 – Sodium-glucose cotransporter 1SGLT2 – Sodium-glucose cotransporter 2 BC Staff Lexicon Pharmaceuticals Inc. Bayer...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

...with the phrase “alternative facts” entering the lexicon...
BioCentury | Dec 31, 2020
Management Tracks

Biden-Harris team picks coordinators for COVID-19 task force; plus moves at Taysha, Alligator and ImmunityBio

...pharmaceutical engineering at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Lee was head of corporate strategy and investor relations at Lexicon Pharmaceuticals Inc....
...was CMO at Apollomics Inc. Danielle Golovin Taysha Gene Therapies Inc. Alligator Bioscience AB ImmunityBio Inc. Apollomics Inc. Ferring Pharmaceuticals A/S Sarepta Therapeutics Inc. Lexicon Pharmaceuticals Inc. COVID-19 cov19pol cov19pol...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...will receive an exclusive option to obtain Deep Genomics’ development and commercialization rights for each program. Lexicon...
...Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Lexicon Pharmaceuticals Inc. Novo...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...have been transformed into manageable, chronic conditions; the word “cure” has been added to the lexicon...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...>96% pure ethyl ester of eicosapentaenoic acid (ethyl-EPA) (see “Panel Backs CV Indication” ). Also, Lexicon Pharmaceuticals Inc....
...the company’s appeal of a complete response letter for sotagliflozin to treat Type I diabetes. Lexicon...
...SAR439954, lx4211 tablet) [MERGED] AstraZeneca plc Shenzhen Chipscreen Biosciences Co. Ltd. Merck & Co. Inc. Amarin Corp. plc Orchard Therapeutics plc Lexicon Pharmaceuticals Inc. AstraZeneca...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

...Sanofi to pay Lexicon $260M as Zynquista ends Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million...
...Phase III failure by the drug. Zynquista is approved in Europe for Type I diabetes. Lexicon...
...still planning to seek regulatory approval in the U.S. and Europe for Type II diabetes. Lexicon...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

...what will and won’t be regulated can’t be fully drawn without absorbing an entirely new lexicon...
BioCentury | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

...Biomarker data lift Lexicon Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week...
...Sodium-glucose cotransporter 1; SGLT2 - Sodium-glucose cotransporter 2 Sandi Wong, Staff Writer BIO89-100 (TEV-47948) TOP1630 Zynquista, sotagliflozin (SAR439954, lx4211 tablet) Lexicon Pharmaceuticals Inc. TopiVert...
BioCentury | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

...Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in...
...rivaroxaban (BAY 59-7939) Xeljanz XR, tofacitinib extended release Zynquista, sotagliflozin (SAR439954, lx4211 tablet) Amarin Corp. plc Galapagos N.V. Johnson & Johnson Lexicon Pharmaceuticals Inc. Pfizer...
Items per page:
1 - 10 of 529
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

...By BioCentury Staff Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its...
...immediately but remains subject to comment. TARGETSSGLT1 – Sodium-glucose cotransporter 1SGLT2 – Sodium-glucose cotransporter 2 BC Staff Lexicon Pharmaceuticals Inc. Bayer...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

...with the phrase “alternative facts” entering the lexicon...
BioCentury | Dec 31, 2020
Management Tracks

Biden-Harris team picks coordinators for COVID-19 task force; plus moves at Taysha, Alligator and ImmunityBio

...pharmaceutical engineering at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Lee was head of corporate strategy and investor relations at Lexicon Pharmaceuticals Inc....
...was CMO at Apollomics Inc. Danielle Golovin Taysha Gene Therapies Inc. Alligator Bioscience AB ImmunityBio Inc. Apollomics Inc. Ferring Pharmaceuticals A/S Sarepta Therapeutics Inc. Lexicon Pharmaceuticals Inc. COVID-19 cov19pol cov19pol...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...will receive an exclusive option to obtain Deep Genomics’ development and commercialization rights for each program. Lexicon...
...Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Lexicon Pharmaceuticals Inc. Novo...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...have been transformed into manageable, chronic conditions; the word “cure” has been added to the lexicon...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...>96% pure ethyl ester of eicosapentaenoic acid (ethyl-EPA) (see “Panel Backs CV Indication” ). Also, Lexicon Pharmaceuticals Inc....
...the company’s appeal of a complete response letter for sotagliflozin to treat Type I diabetes. Lexicon...
...SAR439954, lx4211 tablet) [MERGED] AstraZeneca plc Shenzhen Chipscreen Biosciences Co. Ltd. Merck & Co. Inc. Amarin Corp. plc Orchard Therapeutics plc Lexicon Pharmaceuticals Inc. AstraZeneca...
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

...Sanofi to pay Lexicon $260M as Zynquista ends Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million...
...Phase III failure by the drug. Zynquista is approved in Europe for Type I diabetes. Lexicon...
...still planning to seek regulatory approval in the U.S. and Europe for Type II diabetes. Lexicon...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

...what will and won’t be regulated can’t be fully drawn without absorbing an entirely new lexicon...
BioCentury | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

...Biomarker data lift Lexicon Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week...
...Sodium-glucose cotransporter 1; SGLT2 - Sodium-glucose cotransporter 2 Sandi Wong, Staff Writer BIO89-100 (TEV-47948) TOP1630 Zynquista, sotagliflozin (SAR439954, lx4211 tablet) Lexicon Pharmaceuticals Inc. TopiVert...
BioCentury | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

...Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in...
...rivaroxaban (BAY 59-7939) Xeljanz XR, tofacitinib extended release Zynquista, sotagliflozin (SAR439954, lx4211 tablet) Amarin Corp. plc Galapagos N.V. Johnson & Johnson Lexicon Pharmaceuticals Inc. Pfizer...
Items per page:
1 - 10 of 529